CN

Company news

Location：

Home

News

Company news

Nanjing Rongjiekang RC1416 dual antibody ha™λ♣₹s obtained 2 clinical trial licenses agaiβ n

Nanjing Rongjiekang RC1416 dual antibody hγα÷as obtained 2 clinical trial licenses again

Categories:Company news
Author:
Origin:
Time of issue:2025-01-03
Views:0





Nanjing Rongjiekang RC1416 dual antibody has ob€αεtained 2 clinical trial licenses again

(Summary description)Recently, Nanjing RegeneCore Biotec™¶♠πhnology Co., Ltd.'s RC1416 project has co↓ ≥nsecutively obtained Inves∏±tigational New Drug (IND) approvals ↔σ✔δfrom the National Medical Prod≠αucts Administration's C'±€★enter for Drug Evaluation ®€(CDE) for indications of atopic dermatitis (AD) ≈×and chronic obstructive pulΩ$λmonary disease (COPD). The expansion of these€ indications has further diversified the c®®©δlinical application scenarios ↕ ≈§of RC1416 injection, providing better Ω¥treatment options for more pa<≠'tients..

Categories:Company news
Author:
Origin:
Time of issue:2025-01-03
Views:0

Information

Recently, Nanjing Rege↔₽π©neCore Biotechnology♣&π Co., Ltd.'s&®→ ♦nbsp;RC1416 project has consecutiv☆ "ely obtained Investigational&nb↓✘∞÷sp;New Drug (IND) '♦₩≠approvals from

the National Medical Produc×∞ ts Administration's Center&n‌≠&bsp;for Drug Evalu&>≈ation (CDE) for indications&nbs☆εp;of atopic dermatiti♦εs (AD) and chronic obstructα★'ive

pulmonary disease (COPD). The×₽✔α expansion of these&n ¶∏bsp;indications has further ₽↑;diversified the clinical&nb×₽sp;application scenarios&nλ÷bsp;of RC1416 injection, providing

better treatment options&nbs↕↑↔p;for more ∑×§patients.

Scan the QR code to r€♣ead on your phone

Previous: None

Next: 融捷集團：競逐新賽道(dào)，勇攀生(shēng)命科(kē)技(jì$×)高(gāo)峰

Previous: None

Next: 融捷集團：競逐新賽道(dào)，勇攀生(shēng)命科(kē)技(jì)高(gāo§)峰

01-03

2025



Nanjing Rongjiekang RC1416 dual antibody has↔♥≠ obtained 2 clinical trial licenses again

Recently, Nanjing Reg©₽eneCore Biotechnology Co., Ltd.'s RC1416 α≤βαproject has consecut€ λively obtained Investigationσ±γal New Drug (IND) appr✔ ©↕ovals from the National Medical₩' Products Administration's Center for∞₩♠ Drug Evaluation (CDE) for indi< cations of atopic dermatitis (AD) and chr¥∑onic obstructive pulmona÷£ry disease (COPD). The expansi<Ω≥on of these indications has further divers©×✘€ified the clinical a"®↓pplication scenarios of RC1416 inj★λσection, providing better treatment options fo λ <r more patients..

12-02

2024



融捷集團：競逐新賽道(dào)，勇攀生(shēng)命科(kē)技(jì)高(gāo)<‌峰

近(jìn)日(rì)，南京博爾迪生物科技"✘Ω有限公司發布的(de)一(yī)則招募中重度哮喘患者的(d≈♣&e)消息引人(rén)關注。原來(lái)，由融捷康自(zì)研的(de)國(guó)®↕©內(nèi)首個(gè)自(zì)免雙特異性納米抗體(tǐ)藥物(wù)——RC14↕≥≈16注射液，正在全國(guó)數(shù)十家(jiā)知(zhī)名醫(y"€βσī)院開(kāi)展臨床研究。這(zhè)款雙抗藥品在藥效、安全性φ≥和(hé)成藥性等多(duō)重指标上(shàng)具有(yǒu)較好(hǎo)的(dε ←e)優勢，未來(lái)有(yǒu)望成為(w<☆≤èi)中重度哮喘患者的(de)福音(yīn)。

11-26

2024



Recruitment of Patients with Modeγ♠ rate to Severe Asthma

RC1416 injection, developed by ≈π‍Nanjing RegeneCore Biotech Cβ¶o.,Ltd, is currently¥↓₽ undergoing a Phase Ib clinica✘©♦₹l study to "evaluate the safety&§ ≤, tolerability, pharmacokine¥©≤♣tics, pharmacodynamics, immunogenic ★ity, and preliminary effectiveness of RC1416 inj€λ↑Ωection in patients with moderate to severe ast&δΩ∞hma." The lead instituΩφ tion for this study is the China-Japan Friendshiλ≠↓©p Hospital in Beijing, and it is simultaneφσously being conducted at dozens of renowned hosp₹§itals across the country.

TEL：

025-58608860

Address: Room 07 Building 16 Tre•÷±ehouse, No. 73, Tanmi Road, J∑ελ>iangbei New District, Nanjing

Enterprise email：rjk@regenecore.com

WeChat cooperative consultation

www.300.cn nanjing 備案号：京ICP證000000号

You are the th visitor